The reporting of larger Phase II and III breast cancer clinical trials have largely focused on ascertaining the safety and clinical outcomes in response to ICB, with little detailed tissue analysis beyond the presence of TILs or expression of PD-L1, which has enriched for responding patients in the metastatic setting but not the early setting. The gene discussed is CD274; the disease is breast carcinoma.